Skip to content
  • Home
  • Health & Tech
  • FDA & EMA
  • Oncology
  • Contact

Pharminent

  • Thoughts from around the web: using ‘Most Favored Nation’ for US Drug Pricing
    by Jason Shafrin (Healthcare Economist) on May 16, 2025

    Lakdawalla and Goldman. Tyler Cowen. AARP. National Pharmaceutical Council (from 2021) BIO. Adam Fein Here is a comparison of the CMS Final Rule (from 2021) vs. 2025 Trump Executive Order.

  • What are concerns with IRA drug price negotiations for part B drugs?
    by Jason Shafrin (Healthcare Economist) on May 16, 2025

    There were lots of very interesting sessions at ISPOR 2025 in Montreal. One of my favorites that I was able to attend was titled “Medicare Price Negotiation of Part B Drugs: Implications for Provider Reimbursement and Commercial Spillover“. The […]

  • How does hospital participation in a Medicare Advantage preferred network impact commercial reimbursement?
    by Jason Shafrin (Healthcare Economist) on May 15, 2025

    How does a hospital’s participation in a health plan’s Medicare Advantage (MA) provider network impact their commercial rates? Since many insurers offer both MA plans and commercial plans, there could be spillovers with respect to negotiating. […]

  • How do drug prices change before loss of exclusivity?
    by Jason Shafrin (Healthcare Economist) on May 14, 2025

    Typically, cost effectiveness analyses assume a constant price between drug approvals and loss of exclusivity. It is not clear, however, to what extent that assumption is valid, particularly after taking into account drug price discounts and […]

  • Links
    by Jason Shafrin (Healthcare Economist) on May 8, 2025

    I’ll be at ISPOR.  Health Care Subscriptions: Who Benefits and Who Gets Left Behind? NIH bans new funding from US scientists to scientists abroad Most favored nation. CDC: RSV vaccine works.

  • Will the Trump Administration implement a Most Favored Nation policy for US drug prices?
    by Jason Shafrin (Healthcare Economist) on May 7, 2025

    Perhaps so according to Politico: Trump early next week is expected to sign an executive order directing aides to pursue the initiative, called “most favored nation,” for a selection of drugs within the Medicare program. The idea would use the […]

  • Do Medicare Advantage plans with high medication adherence rates do well on Medicare Advantage Star ratings?
    by Jason Shafrin (Healthcare Economist) on May 7, 2025

    The answer is ‘yes’ according to a paper by Borrelli et al. (2025). The authors use annual Medicare Star Rating health plan performance for Medicare Advantage-Part D (MAPD) plans over the past decade (2015 to 2024). They find that: For plans […]

  • Why is Affordable housing so expensive?
    by Jason Shafrin (Healthcare Economist) on May 6, 2025

    From Coby Lefkowitz in Building Optimism: In Los Angeles, “luxury” units in non-high-rises can be delivered for around $300,000 to $400,000 per unit. Non-“luxury” market rate units can be completed for half of that, conditional on their size […]

  • ISPOR 2025 in Montréal
    by Jason Shafrin (Healthcare Economist) on May 5, 2025

    Three panels. One great city. Can’t wait for the conversations at ISPOR 2024 in Montréal. GCEA: Where do we go from here? (14 May, 5-6pm) Should we finally rethink the 3% discount rate? (15 May, 3:15-4:15pm) How can HEOR support providers in […]

  • Links
    by Jason Shafrin (Healthcare Economist) on May 2, 2025

    Innovative Payment Models for Sickle-Cell Disease Gene Therapies. EHR records transfer: fax, CD, mail. ‘Why public health must always be led by economists’ Impact of federal cuts and inflation on food banks. End of an era?

RSS News – European Pharmaceutical Review

  • Novo Nordisk CEO to exit role May 16, 2025
  • Takeda investigational drug shows efficacy in narcolepsy May 15, 2025
  • GSK to expand hepatology pipeline with potential best-in-class therapy May 14, 2025
  • Novel breast cancer treatment approach significantly enhances survival May 13, 2025
  • World-first approval supports AstraZeneca’s sustainability goals May 12, 2025
  • Innovative CAR T therapy could deliver in broader therapeutic settings, research suggests May 9, 2025

RSS Big Molecule Watch

  • Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with STELARA (ustekinumab) May 16, 2025
  • Join Us! The Future of Biotech Regulation Webinar May 16, 2025
  • Third Circuit Affirms Rejection of AstraZeneca’s Challenges to IRA Drug Price Negotiation Program May 15, 2025
  • President Trump Issues Two Executive Orders Concerning the Affordability and Accessibility of Drugs May 15, 2025
  • EMA Issues Positive CHMP Opinions for Biocon’s Denosumab Biosimilars May 9, 2025

RSS Drug Channels

  • Resetting the Walk-Away Price: How GoodRx Data Reveals New Realities of Prescription Abandonment May 16, 2025
  • How Large PBMs Make Money Today: A 2025 Drug Channels Update May 13, 2025
  • From Barriers to Bridges: Rethinking Medication Access for 2025 May 9, 2025
  • Follow the 340B Dollar: Senator Cassidy Exposes How CVS Health and Walgreens Profit as 340B Contract Pharmacies May 6, 2025
  • Claritas Rx’s Webinar: Achieve Specialty Pharma Success with AI: Enhance Care, Elevate Fill Rates by 20% and Improve Patient Adherence May 5, 2025
  • Unlocking the Gate: The Critical First 24 Hours of Patient Hub Engagement May 2, 2025
  • Drug Channels News Roundup, April 2025: Amazon Rx Update, Express Scripts’ Spend Trends, Gold Cards, and CMS Acronym Absurdity April 28, 2025

Sign Up to Receive Updates

Check your inbox or spam folder to confirm your subscription.

@ 2025 Pharminent. All rights reserved

Design by ThemesDNA.com